



Financial Tear Sheet

Corporate Profile

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders.

Primary IR Contact

MacDougall Biomedical
Communications
Karen Sharma
Phone: 781-235-3060
E-mail:
ksharma@macbiocom.com

Recent Headlines & Events

	Date	Title
10/02/18 - 7:01 a.m. <u>Exicure Presents First Data Demonstrating Both Oral Delivery and Liver Delivery of Spherical Nucleic Acid Constructs in Animal Models</u>	10/17/18 through 10/18/18	<u>The 8th annual Partnership Opportunities in Drug Delivery</u> Location Boston, MA
10/01/18 - 7:00 a.m. <u>Data on Exicure's TLR9 Agonist Spherical Nucleic Acid (SNA™) Construct Presented at the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference</u>	10/25/18	<u>BTIG Biotech Conference</u> Location Langham Hotel New York, NY
09/28/18 - 7:00 a.m. <u>Exicure, Inc. to Present at Upcoming Investor Conference and Participate in Oncology Roundtable</u>	11/05/18 through 11/07/18	<u>BIO-Europe 2018</u> Location CopenhagenDK

SEC Filings

Filing Date	Form
10/11/18	<u>424B3</u>

10/10/18	<u>8-K</u>
10/09/18	<u>424B3</u>
10/05/18	<u>EFFECT</u>

Data provided by Nasdaq. Minimum 15 minutes delayed.